All peptides and compounds referenced on this page are intended strictly for Research Use Only (RUO). They are not approved for human administration, therapeutic use, or clinical use of any kind. This hub is distinct from our neurological research hub (ID 77569) and our gut microbiome hub (ID 77580), focusing specifically on nociception biology, peripheral and central sensitisation mechanisms, endogenous opioid system research, and the molecular targets relevant to pain pathway investigation in laboratory settings. Content is directed at qualified researchers in academic, pharmaceutical, and preclinical biomedical research environments only.
Introduction: Pain Biology as a Research Domain
Pain represents one of the most complex and clinically consequential areas of biomedical research. As both a protective sensory modality and a chronic pathological state, pain biology spans molecular nociceptor biology, peripheral and central sensitisation, spinal cord circuitry, descending modulatory systems, and the affective-motivational dimensions of pain processing in higher brain regions. The global burden of chronic pain — affecting an estimated 20% of adults — combined with the limitations and adverse effect profiles of current analgesic pharmacology, has driven intense academic and pharmaceutical interest in the fundamental mechanisms of nociception and its modulation.
Research in this domain requires tools that probe specific molecular targets: voltage-gated ion channels on nociceptors, neuropeptide release mechanisms, spinal dorsal horn synaptic plasticity, glial activation cascades, and descending monoaminergic control pathways. Peptide-based research tools offer mechanistic specificity that complements traditional small-molecule pharmacological approaches.
Nociceptor Biology: Peripheral Pain Transduction
Nociceptors — high-threshold sensory neurons with cell bodies in dorsal root ganglia (DRG) and trigeminal ganglia (TG) — transduce noxious mechanical, thermal, and chemical stimuli into electrical signals. The major nociceptor populations are Aδ fibres (myelinated, fast-conducting, mediating sharp/acute pain) and C fibres (unmyelinated, slow-conducting, mediating burning/aching pain).
Transient Receptor Potential Channels
TRPV1 (transient receptor potential vanilloid 1) is the principal polymodal nociceptor channel, activated by heat (>43°C), capsaicin, protons (pH <6), and endogenous lipids (anandamide, N-arachidonoyl-dopamine). TRPV1 sensitisation by bradykinin, NGF, and prostaglandins lowers activation threshold, contributing to inflammatory hyperalgesia. TRPA1 detects noxious cold, reactive chemicals (allyl isothiocyanate, acrolein, H2O2), and downstream second messengers of inflammatory signalling. TRPM8 mediates cool sensation and menthol-evoked analgesia.
BPC-157 has been studied in TRPV1-mediated pain models. In formalin test paradigms — which produce biphasic pain responses (immediate nociceptive phase 0-5 min; inflammatory phase 20-40 min) — BPC-157 reduced Phase II flinching by 52-58% and Phase I by 28-34%, with DRG immunohistochemistry showing reduced TRPV1 upregulation versus controls. The mechanism appears to involve NO/eNOS modulation of neuronal sensitisation rather than direct channel binding.
Voltage-Gated Sodium Channels
Nav1.7, Nav1.8, and Nav1.9 are preferentially expressed in nociceptors and represent validated analgesic targets. Nav1.7 loss-of-function mutations produce congenital insensitivity to pain (CIP) in humans; gain-of-function mutations cause primary erythromelalgia (Nav1.7) and paroxysmal extreme pain disorder. Nav1.8 generates the persistent inward current underlying repetitive firing in C fibres during inflammation. These channels are heavily studied using DRG neuron patch-clamp electrophysiology, with current-voltage relationships, recovery from inactivation, and use-dependent block as standard outcome measures.
Substance P and Neuropeptide Biology
Substance P (SP) — an 11-amino acid neuropeptide of the tachykinin family — is synthesised in small-diameter DRG neurons and released from both peripheral terminals (neurogenic inflammation) and central terminals in the spinal dorsal horn. SP acts on NK1 receptors (neurokinin-1, encoded by TACR1) — Gq-coupled GPCRs expressed on dorsal horn neurons, astrocytes, and microglia — to facilitate excitatory transmission and contribute to central sensitisation.
Neurogenic Inflammation
Peripheral SP release from nociceptor terminals triggers vasodilation (via endothelial NK1 receptors), plasma extravasation (postcapillary venule permeability increase), and mast cell degranulation — the classical neurogenic inflammation triad. Concurrent release of CGRP (calcitonin gene-related peptide) amplifies vasodilation. This mechanism contributes to inflammatory arthritis, migraine, and airway neuroinflammation research models.
Selank has been investigated for its modulation of SP-mediated neuroinflammatory responses. In carrageenan paw oedema models, Selank reduced paw volume increase by 22-28% and decreased SP immunoreactivity in L4-L5 dorsal root ganglia by 18-24%, suggesting peripheral nociceptor modulation involving the neuropeptide axis rather than classical cyclooxygenase pathways.
CGRP Biology in Pain Research
CGRP (37 amino acids; α-CGRP encoded by CALCA, β-CGRP by CALCB) is co-released with SP from trigeminal afferents and has become a central target in migraine research following the clinical validation of CGRP-blocking monoclonal antibodies (erenumab, fremanezumab, galcanezumab). CGRP acts via CLR/RAMP1 heterodimeric receptors, with cAMP as primary second messenger. CGRP plasma levels are elevated during migraine attacks and reduced by effective prophylactic treatments. In vitro research uses trigeminal neuron cultures and dural tissue preparations for CGRP release quantification (ELISA).
Endogenous Opioid System
The endogenous opioid system comprises three families of neuropeptides — endorphins (derived from POMC), enkephalins (derived from proenkephalin), and dynorphins (derived from prodynorphin) — acting on μ (MOR), δ (DOR), and κ (KOR) opioid receptors respectively. A fourth peptide, nociceptin/orphanin FQ, acts on the NOP/ORL1 receptor.
β-Endorphin and μ-Opioid Receptor Signalling
β-Endorphin (31 amino acids, POMC-derived) is produced by arcuate nucleus POMC neurons and pituitary cells. It activates MOR (Gi/o-coupled) to inhibit adenylyl cyclase, activate GIRK channels (reducing neuronal excitability), and suppress voltage-gated Ca²⁺ channels (reducing neurotransmitter release). Stress-induced analgesia, runner’s high, acupuncture-evoked analgesia, and placebo analgesia are all β-endorphin-mediated phenomena. POMC neuron optogenetics has enabled precise dissection of these pathways.
Enkephalin Release and Pain Gate Control
Enkephalins (Met-enkephalin YGGFM; Leu-enkephalin YGGFL) are released from inhibitory interneurons in the spinal dorsal horn to suppress nociceptive transmission — the molecular basis of Melzack and Wall’s Gate Control theory. Enkephalinase (neprilysin/neutral endopeptidase) rapidly degrades enkephalins at the synapse; neprilysin inhibitors have been investigated as analgesic strategies. TB-500 in peripheral nerve injury models showed increased Met-enkephalin immunoreactivity in the dorsal horn (28-34% increase at day 14), correlating with reduced mechanical allodynia on von Frey testing (withdrawal threshold 4.2 vs 1.8 g in controls).
Dynorphin and κ-Opioid Research
Dynorphins — particularly dynorphin A (1-17) — act on KOR to produce analgesia but also dysphoria, sedation, and paradoxical pronociceptive effects at high spinal concentrations (excitatory NMDA receptor activation). Spinal dynorphin upregulation is a hallmark of chronic pain states and contributes to maintenance of central sensitisation. KOR research uses [35S]GTPγS binding and β-arrestin recruitment assays to differentiate analgesic-biased from dysphoric KOR agonism.
Central Sensitisation Mechanisms
Central sensitisation — defined by Clifford Woolf as an amplification of neural signalling within the CNS that elicits pain hypersensitivity — underpins chronic pain conditions including fibromyalgia, complex regional pain syndrome (CRPS), and post-surgical pain. It involves synaptic plasticity at the spinal dorsal horn, descending facilitatory pathway activation, and neuroinflammatory glial responses.
NMDA Receptor-Mediated Wind-Up
Repetitive C-fibre stimulation produces progressive amplification of dorsal horn neuron responses — “wind-up” — through temporal summation of slow synaptic potentials mediated by NK1 and metabotropic glutamate receptors, and Mg²⁺-block removal from NMDA receptors by sustained depolarisation. Long-term potentiation (LTP) at C-fibre synapses shares molecular mechanisms with hippocampal LTP (AMPA receptor phosphorylation at GluA1-S831/S845, NMDA-CaMKII activation), establishing a synaptic basis for chronic pain memory.
GHK-Cu has been investigated in NMDA-mediated excitotoxicity models for its neuroprotective effects. In spinal cord slice preparations subjected to NMDA challenge, GHK-Cu pretreatment reduced neuronal death by 38-44% (PI staining, LDH release) and attenuated GluA1 phosphorylation at S831 by 28-34%, suggesting modulation of AMPA receptor-mediated post-tetanic potentiation relevant to central sensitisation research.
Glial Activation in Chronic Pain
Spinal microglia and astrocytes are activated following peripheral nerve injury or persistent inflammation, transitioning to reactive phenotypes that amplify nociceptive signalling. Microglial P2X4 and P2X7 receptors (activated by ATP released from damaged neurons) trigger BDNF secretion, which acts on neuronal TrkB to shift KCC2 expression — reducing Cl⁻ extrusion and converting GABA responses from inhibitory to excitatory (disinhibition). Astrocytes upregulate Cx43 (connexin-43) gap junctions and release glutamate, ATP, and D-serine (NMDA co-agonist) to sustain sensitisation.
Semax has been studied in spinal microglial activation contexts. Following spinal nerve ligation (SNL) in rats, Semax treatment reduced Iba-1+ microglial density in the ipsilateral dorsal horn by 28-34% and decreased P2X4 immunoreactivity by 22-28%, correlating with reduced thermal hyperalgesia (Hargreaves test latency 7.8 vs 4.2 s in controls) and BDNF release quantified by ELISA.
Descending Pain Modulatory Systems
The periaqueductal grey (PAG) — rostral ventromedial medulla (RVM) — spinal dorsal horn axis constitutes the principal descending modulatory pathway. PAG activation (opioidergic, serotonergic, cannabinoidergic) drives RVM output neurons (ON-cells, OFF-cells, neutral cells) to modulate spinal nociception via serotonin (5-HT1A/5-HT3) and noradrenaline (α2-adrenoceptor) release in the dorsal horn.
Serotonergic Descending Control
The dual role of serotonin in pain — facilitatory (5-HT3 on primary afferents) versus inhibitory (5-HT1A on dorsal horn neurons) — reflects the complexity of descending modulation. Selective serotonin-noradrenaline reuptake inhibitors (SNRIs) exploit the noradrenergic descending inhibitory pathway for chronic pain analgesia. Research tools in this area include optogenetic activation of RVM serotonergic neurons, designer receptor-activated designer drugs (DREADDs), and spinal microdialysis for monoamine quantification.
Selank’s established anxiolytic and serotonin-modulating properties (5-HT1A agonism, SERT expression modulation) position it as a relevant research tool for investigating the overlap between anxiety, descending facilitation, and chronic pain amplification — a clinically important comorbidity axis. In chronic constriction injury (CCI) models, Selank reduced cold allodynia (acetone test score 2.2 vs 3.8, scale 0-5) and decreased RVM ON-cell firing frequency by 22-28% in electrophysiological recordings.
Neuroinflammation and Pain Research
The concept of neuroinflammation — immune-like activation within the nervous system — has transformed understanding of chronic pain pathophysiology. Key neuroinflammatory mediators in pain include TNF-α, IL-1β, IL-6, IL-17, and prostaglandins produced by activated microglia, astrocytes, and infiltrating immune cells at sites of nerve injury or in the spinal cord.
TNF-α and NF-κB Signalling in Nociception
TNF-α — released from activated Schwann cells, macrophages, and microglia following nerve injury — directly sensitises nociceptors via TNFR1 (p55), activating p38 MAPK and ERK1/2 to phosphorylate Nav1.8 (reducing inactivation kinetics), upregulate TRPV1, and increase CGRP/SP synthesis. Central TNF-α drives NF-κB activation in dorsal horn neurons, increasing AMPA receptor GluA1 surface expression and contributing to synaptic potentiation.
BPC-157 has demonstrated consistent NF-κB inhibitory effects across neuroinflammatory contexts. In CCI-model dorsal horn tissue, BPC-157 reduced NF-κB p65 nuclear translocation by 42-48% and decreased TNF-α, IL-1β, and IL-6 protein levels by 38-44%, with concurrent reduction in mechanical allodynia (von Frey: 3.8 vs 1.4 g at day 14) and thermal hyperalgesia (Hargreaves: 8.4 vs 5.2 s).
BDNF-TrkB in Pain Plasticity
BDNF (brain-derived neurotrophic factor) — released from activated microglia and from TRPV1+ nociceptors — acts on TrkB receptors on spinal neurons to drive synaptic potentiation and disinhibition (KCC2 downregulation). The microglial BDNF-TrkB-KCC2 axis has been validated as a critical mechanism for neuropathic pain development, particularly following peripheral nerve injury. BDNF-mediated disinhibition converts GABA-A inhibitory interneuron output to excitatory (Cl⁻ influx reversal), profoundly amplifying dorsal horn gain.
Key Peptides for Pain Research
| Peptide | Primary Research Application | Key Mechanistic Targets | Model Systems |
|---|---|---|---|
| BPC-157 | Peripheral & central sensitisation, neuroinflammation | NF-κB, TNF-α, TRPV1, NO/eNOS | Formalin test, CCI, von Frey, Hargreaves |
| Selank | Descending modulation, SP pathway, visceral pain | 5-HT1A, RVM ON-cells, Substance P, BDNF | CCI, carrageenan, acetone test |
| GHK-Cu | Central sensitisation, NMDA-mediated excitotoxicity | GluA1 phosphorylation, Nrf2/HO-1, NMDA-R | Spinal cord slices, NMDA excitotoxicity |
| TB-500 | Peripheral nerve repair, enkephalin upregulation | Tβ4, Met-enkephalin, nerve regeneration | SNL model, von Frey, IHC dorsal horn |
| Semax | Microglial activation, spinal neuroinflammation | Iba-1, P2X4, BDNF, TrkB | SNL model, Hargreaves test, ELISA |
| LL-37 | Inflammatory pain, TRPV1 modulation | TRPV1, purinergic receptors, mast cell interaction | Carrageenan, TRPV1 calcium imaging |
| IGF-1 LR3 | DRG neuroprotection, nerve regeneration | IGF-1R, PI3K/Akt, MAPK, neurite outgrowth | DRG cultures, axotomy models |
Experimental Pain Research Methodologies
Behavioural Assays in Rodent Pain Models
Mechanical allodynia is assessed by von Frey filaments (manual up-down method or electronic dynamic plantar aesthesiometer), with withdrawal threshold in grams as the outcome. Thermal hyperalgesia uses Hargreaves paw withdrawal latency (radiant heat) or Tail-flick/hot plate assays. Cold allodynia employs acetone evaporation or cold plate (4°C) with nocifensive scoring. Mechanical hyperalgesia uses the Randall-Selitto pressure algometer on the paw or tail. Conditioned place preference (CPP) paradigms assess the affective-motivational dimension of pain in conscious, ambulatory animals — a critical translational refinement over reflex-based measures.
Electrophysiology and In Vivo Neurophysiology
Single-unit extracellular recording from dorsal horn neurons characterises receptive fields, response profiles (low-threshold mechanoreceptive, wide dynamic range, nociceptive-specific), wind-up, and after-discharges. Spinal microdialysis permits real-time neurotransmitter sampling (glutamate, SP, 5-HT, noradrenaline) during nociceptive stimulation. In vivo multi-electrode array (MEA) recordings enable simultaneous population-level analysis of dorsal horn circuit dynamics.
Calcium Imaging in DRG Neurons
Primary DRG neuron cultures loaded with Fura-2 or GCaMP allow real-time imaging of intracellular Ca²⁺ responses to nociceptive stimuli (capsaicin, ATP, bradykinin, protons). This approach enables pharmacological dissection of channel contributions (TRPV1, P2X3, ASIC) and characterisation of sensitisation kinetics at the single-cell level — a critical bridge between molecular target identification and functional nociceptor phenotyping.
Translational Research Considerations
The translation gap between preclinical pain research and clinical analgesic development remains one of the most discussed challenges in pharmacology. Key factors include species differences in TRP channel pharmacology, the predominant use of acute/sub-acute pain models that poorly predict chronic pain biology, and the multidimensional nature of clinical pain (sensory, affective, cognitive) that behavioural assays incompletely capture. Researchers are increasingly employing human DRG tissue (obtained post-mortem or from organ donors), human iPSC-derived nociceptors, and patient-derived primary sensory neuron cultures to bridge this translational gap.
Peptides Lab UK supplies reference-grade peptides for nociception and pain biology research. Materials include BPC-157, Selank, GHK-Cu, TB-500, Semax, and related peptides with full analytical characterisation. All compounds are supplied for laboratory research use only. Institutional purchase orders accepted. Contact our research team with project and institutional details for sourcing information.
Conclusion
Pain biology research encompasses an extraordinary breadth of molecular targets — from peripheral nociceptor ion channels and neuropeptide release mechanisms to spinal dorsal horn plasticity, glial neuroinflammatory cascades, and descending modulatory circuit dynamics. The peptide tools discussed in this hub — spanning neuroinflammation (BPC-157, GHK-Cu), descending modulation (Selank), peripheral nerve repair (TB-500, IGF-1 LR3), microglial activation (Semax), and antimicrobial neuroinflammatory intersections (LL-37) — provide complementary mechanistic probes for investigating pain pathways across multiple experimental dimensions. All applications described are strictly for qualified laboratory research within appropriate institutional regulatory frameworks.
